Adrian Gerold Sacher
University Health Network · 400 works · 9,786 citations · h-index 42
Top works
- Sotorasib for Lung Cancers with KRAS p.G12C Mutation
- KRAS G12C Inhibition with Sotorasib in Advanced Solid Tumors
- Prospective Validation of Rapid Plasma Genotyping for the Detection ofEGFRandKRASMutations in Advanced Lung Cancer
- Bias-Corrected Targeted Next-Generation Sequencing for Rapid, Multiplexed Detection of Actionable Alterations in Cell-Free DNA from Advanced Lung Cancer Patients
- Biomarkers for the Clinical Use of PD-1/PD-L1 Inhibitors in Non–Small-Cell Lung Cancer
- Association Between Younger Age and Targetable Genomic Alterations and Prognosis in Non–Small-Cell Lung Cancer
- Chemical genetics reveals a complex functional ground state of neural stem cells
- Single-Agent Divarasib (GDC-6036) in Solid Tumors with a KRAS G12C Mutation
- Acquired MET D1228V Mutation and Resistance to MET Inhibition in Lung Cancer
- PD‐L1 expression in non‐small cell lung carcinoma: Comparison among cytology, small biopsy, and surgical resection specimens
- 459MO Phase Ia study to evaluate GDC-6036 monotherapy in patients with solid tumors with a KRAS G12C mutation
- Long-Term Outcomes and Molecular Correlates of Sotorasib Efficacy in Patients With Pretreated KRAS G12C-Mutated Non–Small-Cell Lung Cancer: 2-Year Analysis of CodeBreaK 100
- Application of Plasma Genotyping Technologies in Non–Small Cell Lung Cancer: A Practical Review
- Elderly Patients with Advanced NSCLC in Phase III Clinical Trials: Are the Elderly Excluded from Practice-Changing Trials in Advanced NSCLC?
- Identification of a bone marrow–derived epithelial-like population capable of repopulating injured mouse airway epithelium
- Real‐world chemotherapy treatment patterns in metastatic non–small cell lung cancer: Are patients undertreated?
- ctDNA response after pembrolizumab in non-small cell lung cancer: phase 2 adaptive trial results
- Shifting Patterns in the Interpretation of Phase III Clinical Trial Outcomes in Advanced Non–Small-Cell Lung Cancer: The Bar Is Dropping
- Clinical outcomes of patients with non-small cell lung cancer (NSCLC) receiving chemotherapy after immune checkpoint blockade.
- CTLA4 blockade abrogates KEAP1/STK11-related resistance to PD-(L)1 inhibitors